- Home
- AVD vs NKTR Comparison
AVD vs NKTR Comparison
Compare AVD & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- NKTR
- Stock Information
- Founded
- AVD 1969
- NKTR 1990
- Country
- AVD United States
- NKTR United States
- Employees
- AVD N/A
- NKTR N/A
- Industry
- AVD Agricultural Chemicals
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- NKTR Health Care
- Exchange
- AVD Nasdaq
- NKTR Nasdaq
- Market Cap
- AVD 135.6M
- NKTR 160.4M
- IPO Year
- AVD N/A
- NKTR 1994
- Fundamental
- Price
- AVD $4.46
- NKTR $0.59
- Analyst Decision
- AVD Strong Buy
- NKTR Strong Buy
- Analyst Count
- AVD 1
- NKTR 6
- Target Price
- AVD $14.00
- NKTR $4.92
- AVG Volume (30 Days)
- AVD 134.0K
- NKTR 2.2M
- Earning Date
- AVD 05-20-2025
- NKTR 05-08-2025
- Dividend Yield
- AVD 0.68%
- NKTR N/A
- EPS Growth
- AVD N/A
- NKTR N/A
- EPS
- AVD N/A
- NKTR N/A
- Revenue
- AVD $553,839,000.00
- NKTR $87,248,000.00
- Revenue This Year
- AVD N/A
- NKTR N/A
- Revenue Next Year
- AVD $4.35
- NKTR N/A
- P/E Ratio
- AVD N/A
- NKTR N/A
- Revenue Growth
- AVD N/A
- NKTR N/A
- 52 Week Low
- AVD $3.28
- NKTR $0.43
- 52 Week High
- AVD $12.67
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- AVD 58.33
- NKTR 39.04
- Support Level
- AVD $4.10
- NKTR $0.57
- Resistance Level
- AVD $4.33
- NKTR $0.81
- Average True Range (ATR)
- AVD 0.19
- NKTR 0.06
- MACD
- AVD 0.06
- NKTR -0.01
- Stochastic Oscillator
- AVD 91.25
- NKTR 7.48
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.